GLP1R and metabolic dysfunction-associated steatotic liver disease: Along the same line, a meta-analysis of twelve RCTs regarding the effect of GLP-1 RAs on liver enzymes and the lipid profile of patients with NAFLD showed that the treatment with GLP-1 RAs reduced ALT, gamma-glutamyl transferase (γGT) and alkaline phosphatase concentrations, suggesting that GLP-1 agonists may have beneficial impact on the treatment of NAFLD, or at least prevent its progression [49].